SV2A and Alzheimer disease: In comparison to placebo, CT1812 treatment in the combined active treatment groups had no significant effect on the change from baseline at 24 weeks in [11C]UCB-J PET-measured SV2A binding as a measure of synaptic density, or in [18F]FDG PET-measured reduction in glucose metabolism in an AD-associated composite region of interest.